Urovant Sciences, a clinical-stage biotech developing oral therapies for OAB, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
The London, United Kingdom-based company was founded in 2016 and plans to list on the Nasdaq under the symbol UROV. Urovant Sciences filed confidentially on May 23, 2018. J.P. Morgan, Jefferies and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
